Tisagenlecleucel for Non-Hodgkin's Lymphoma (JULIET Trial)

"As of October 2nd, 2022, this study is no longer seeking candidates. It was initially posted on July 29th, 2015. If you are looking for other trials, there are 1810 lymphoma studies and 18 CTL019 clinical trials currently recruiting patients."

"Currently, there are 18 ongoing clinical trials researching CTL019. Out of those active studies, 2 have reached Phase 3 status. The majority of the trials for CTL019 are based in Washington D.C., but 331 locations across the globe are running medical research for this treatment."

"Various hospitals and clinics are participating in this trial, such as University of California San Francisco SC-4 in San Francisco, California; Novartis Investigative Site in Hamilton, Ontario; and University of Chicago Medical Center, Hematology & Oncology in Chicago, Illinois."

"Since 2015, CTL019 has undergone 19 different clinical trials. The first was sponsored by Novartis Pharmaceuticals and took place in 2015 with 97 participants. Phase 2 approval was granted after the successful completion of the first study. Currently, there are 18 ongoing trials being conducted in 115 cities and 22 countries worldwide."

"CTL019's safety is supported by some data, but as this is only a Phase 2 trial, there is no evidence yet of efficacy. We've given it a score of 2."

"Although this particular study is no longer recruiting patients, the data available on clinicaltrials.gov suggests that it was last edited on 10/2/2022. There are 1828 other trials which are actively looking for participants right now."